Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: results of monotherapy and combination therapy trials
作者: Alecu IMilenkova TTurner SR
刊名: Drug Design, Development and Therapy, 2018, Vol.Volume 12 , pp.347-348
来源数据库: Directory of Open Access Journals
关键词: Hematologic toxicitiesPARP inhibitorsOlaparibNeutropenia
原始语种摘要: Iulian Alecu, Tsveta Milenkova, Simon R Turner Research and Development, AstraZeneca UK Limited, Cambridge, UKThe tolerability profile of PARP inhibitors often includes hematologic toxicities, and the characterization of these adverse events is important to allow effective management by clinicians. Zhou et al1 recently carried out a meta-analysis of the incidence and relative risks of severe neutropenia, thrombocytopenia, and anemia events in 12 randomized controlled trials of PARP inhibitors, either as monotherapy or in combination with chemotherapy or radiotherapy. The authors concluded that olaparib resulted in a higher incidence of severe (common terminology criteria for adverse events [CTCAE] grade $3) neutropenia when compared with niraparib and veliparib; however, these conclusions...
全文获取路径: PDF下载  DOAJ  (合作)
影响因子:3.486 (2012)

  • monotherapy 硫化物
  • hematologic 血液学的
  • combination 聚形
  • chemotherapy 化学疗法
  • neutropenia 中性白细胞增多
  • carboplatin 卡波铂
  • cancer 癌症
  • events 定时
  • inappropriate 不适当的
  • toxicity 毒性